What’s new
ColoProg becomes OncoProg
Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ® OXFORD, UK
ToxNav ® validation data published
Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal
HAPB3 joins the ToxNav panel
The team at Oxford Cancer Biomarkers (OCB) are pleased to announce the expansion of our ToxNav® DPYD genomics panel with
Colorectal cancer in the Covid-19 era
Professors David and Rachel Kerr’s proposed colorectal cancer treatment guidelines for patients during the COVID-19 era. AIMS To reduce the
Launching the 5FU Test Alliance
Today I am incredibly proud to be supporting the launch of the 5FU Test Alliance support group. They comprise a
OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients
Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology
Oxford Cancer Biomarkers appoints a Medical Science Liaison Manager to strengthen operations and support continued growth
Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen
Oxford Cancer Biomarkers hires two Senior Operations and Quality Control Specialists to help manage continued growth
For immediate release: 22 August 2019 Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to